









The Centre for Health Economics Research and Evaluation (CHERE) was 
established in 1991.  CHERE is a centre of excellence in health economics and 
health services research. It is a joint Centre of the Faculties of Business 
and Nursing, Midwifery and Health at the University of Technology, Sydney, in 
collaboration with Central Sydney Area Health Service. It was established as a 
UTS Centre in February, 2002. The Centre aims to contribute to the development 
and application of health economics and health services research through 
research, teaching and policy support. CHERE’s research program encompasses 
both the theory and application of health economics. The main theoretical 
research theme pursues valuing benefits, including understanding what 
individuals value from health and health care, how such values should be 
measured, and exploring the social values attached to these benefits. The 
applied research  focuses on economic and the appraisal of new programs or new 
ways of delivering and/or funding services. CHERE’s teaching includes 
introducing clinicians, health services managers, public health professionals 
and others to health economic principles. Training programs aim to develop 
practical skills in health economics and health services research. Policy 
support is provided at all levels of the health care system by undertaking 
commissioned projects, through the provision of formal and informal advice as 



















University of Technology, Sydney 
City campus, Haymarket 
PO Box 123 Broadway NSW 2007 
Tel: +61 2 9514 4720  


















Men’s preferences for treatment of early stage prostate cancer: 


























1.  Centre for Health Economics Research and Evaluation 
Faculty of Business 
University of Technology, Sydney 
2.  Cancer Council NSW, Sydney, Australia. 
3.  Sydney Cancer Centre and University of Sydney, Australia. 
 
 









Prostate cancer is the most common cancer in men in Australia; each year over 10,000 
Australians are diagnosed with this disease. There are a number of treatment options for 
early stage prostate cancer (ESPC); radical prostatectomy, external beam radiotherapy, 
brachytherapy, hormonal therapy and combined therapy. Treatment can cause serious 
side-effects, including severe sexual and urinary dysfunction, bowel symptoms and 
fatigue.  Furthermore, there is no evidence as yet to demonstrate that any of these 
treatments confers a survival gain over active surveillance (watchful waiting). While 
patient preferences should be important determinants in the type of treatment offered, 
little is known about patients’ views of the relative tolerability of side effects and of the 
survival gains needed to justify these. To investigate this, a discrete choice experiment 
(DCE) was conducted in a sample of 357 men who had been treated for ESPC and 65 
age-matched controls. The sample was stratified by treatment, with approximately equal 
numbers in each treatment group. The DCE included nine attributes: seven side-effects 
and two survival attributes (duration and uncertainty). An orthogonal fractional set of 108 
scenarios from the full factorial was used to generate three versions of the questionnaire, 
with 18 scenarios per respondent. Multinomial logit (MNL) and mixed logit (MXL) 
models were estimated.  A random intercept MXL model provided a significantly better 
fit to the data than the simple MNL model, and adding random coefficients for all 
attributes dramatically improved model fit. Each side-effect had a statistically significant 
mean effect on choice, as did survival duration. Most attributes had significant variance 
parameters, suggesting considerable heterogeneity among respondents in their 
preferences.  To model this heterogeneity, we included men’s health-related quality of 
life scores following treatment as covariates to see whether their preferences were 
influenced by their previous treatment experience. This study demonstrate how DCEs can 
be used to quantify the trade-offs patients make between side-effects and survival gains. 
The results provide useful insights for clinicians who manage patients with ESPC, 
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Some 680,000 men worldwide were diagnosed in 2002 with prostate cancer, which was 
second only to lung cancer (965,000 diagnosed), as the most common cancer in males
1. 
In developed countries prostate cancer is now the most common male cancer, ahead of 
lung and bowel cancer, but is ranked fifth, behind lung, stomach, liver and bowel cancer 
in developing countries (Ferlay, Bray et al. 2004). Incidence increased dramatically in 
many developed countries during the 1980s and 1990s. For example, according to SEER 
data from cancer registries in the USA, age-adjusted incidence increased from 119 per 
100,000 in 1986 to a peak of 237 in 1992 and then fell and stabilised at about 180 per 
100,000 from 1999, a level still 50% more than 13 years earlier (Ries, Harkins et al. 
2005).  Survival from prostate cancer compares well with that from other cancers and has 
increased substantially in the last two decades in the USA (Ries, Harkins et al. 2005) and 
in most European countries (Coleman, Gatta et al. 2003) . The extent to which these 
increases in incidence and survival reflect earlier detection and more effective, newer 
treatments is unknown. Regardless of the reasons for the trends, the consequence is that 
more men are receiving treatment for early stage prostate cancer.  
There are a number of treatment options for early stage prostate cancer; radical 
prostatectomy, radical external beam radiotherapy, brachytherapy (interstitial 
radiotherapy), hormonal therapy, combined therapy and “watchful waiting” (active 
surveillance but no active treatment). Each one has significant associated morbidity; the 
most important morbid consequences are incontinence, impotence and proctitis 
associated with prostatectomy and radiotherapy. Other complications include, major 
bleeding, bladder neck contraction, cystitis, urethral stricture, rectal incontinence or 
complications, urethral necrosis, perineal pain, hematuria and death. Furthermore, there is 
no evidence as yet to demonstrate that any of these treatments confers a survival gain 
over watchful waiting.  
Patient preference should be an important factor in treatment decisions in early stage 
prostate cancer, since men will vary in the value they place on quality versus quantity of 
life, and on different aspects of quality of life, which in turn are influenced by treatment 
side-effects (National Health and Medical Research Council (NHMRC) 2003).  Despite 
this, current management practices are primarily determined by patient age, patient 
fitness and tumour characteristics.  Lack of knowledge and systematic study of patients’ 
values and preferences in this context may explain the lack of inclusion of patient 
preferences in treatment decisions.  
A number of studies have focussed on patient preferences in prostate cancer. The 
majority of these studies used Time Trade Off (TTO) and Standard Gamble (SG) to elicit 
preferences, and all investigated men’s attitudes to side effects and health states 
associated with the management of prostate cancer.  In terms of the trade off between 
quantity and quality of life, Bruner et al (2004) found that men were willing to trade very 
little, ≥ 1% of a 5yr life expectancy, for improved urinary and sexual function. Smith et al 
(2002) and Saigal et al (2001) also found that men placed more weight of survival time 
than quality of life.  Many of these studies results focussed on sexual and urinary 
dysfunction, but when addition side effects such as pain or loss of physical strength were 
included, these were found to be as or more important (Chapman, Elstein et al. 1999;  
 
Knight, Nathan et al. 2002; Krahn, Ritvo et al. 2003; Knight, Siston et al. 2004; Jenkins, 
Fallowfield et al. 2005; Stewart, Lenert et al. 2005). Sculpher et al (2004), the only paper 
found to have used a DCE, included eight attributes using two levels and found that on 
average participants were most willing to give up life expectancy to avoid limitations in 
physical energy and least willing to trade to avoid hot flushes.  
The purpose of this study was to determine, from the patient’s perspective, the relative 
tolerability of a wide range of side-effects of treatment for localized prostate cancer and 
the survival gains needed to make current treatment options worthwhile. 
METHODS 
Sample  
We conducted a discrete choice experiment (DCE) in a random subsample of men 
enrolled in the NSW Prostate Cancer Outcomes Study (PCOS). PCOS is a population-
wide investigation of quality of life, recurrence and survival in men aged less than 70 
years who were newly diagnosed with prostate cancer in New South Wales (NSW), 
Australia, from September 2000 to October 2002. Participants were ascertained through 
the NSW Central Cancer Registry, a state-wide register of all cancers. The Cancer 
Council NSW Human Research Ethics Committee approved the study. 
 
All PCOS participants have been undertaking annual telephone interviews measuring 
their quality of life, up to 5 years from diagnosis.  Since the preferences of men may be 
influenced by their previous treatment experience, the DCE subsample was stratified by 
actual treatment; radical prostatectomy, external beam radiotherapy, brachytherapy (high 
and low dose), hormonal therapy, combined therapy, active surveillance (watchful 
waiting) and controls, giving seven ‘treatment’ groups with approximately equal numbers 
in each treatment group.   
 
Experimental design and sample size 
 
The total sample size was based on the degrees of freedom required to estimate all 
parameters of interest associated with the experimental design, which in turn was 
determined by the number of attributes and levels in the DCE.  The DCE contained nine 
attributes, each with three levels, giving 3
9 possible scenarios.  A fractional set of 108 
scenarios from the full factorial provided sufficient degrees of freedom to estimate all 
main effects and two-way interactions. These could be allocated into questionnaires in 
two ways: 18 choice sets each containing a pair of scenarios (3 versions of this style of 
questionnaire would be required) or 9 choice sets each containing a trio of scenarios (4 
versions of this style of questionnaire would be required); the two styles were tested in a 
pilot (described below), and the paired-scenario option was preferred. Thus a sample of 
420 respondents was deemed sufficient, allowing for 20 respondents per treatment group 
per version; past experience suggests that 20-30 respondents per version are sufficient for 
adequate precision, while some authors recommend as few as six (Louviere, Hensher et 
al. 2000).  Respondents were randomly sampled by strata and recruited by telephone by 
staff at the Cancer Council NSW before being sent a questionnaire and survey 
information pack in the post. They were then contacted by telephone by the same group  
 
of interviewers from the Hunter Valley Research Foundation (HVRF) who have been 
contacting the men annually for other aspects of the PCOS data collection. Participants 
were randomly assigned to questionnaire version within each treatment strata. 
DCE Attributes and Levels 
The attributes were developed from the literature on health related quality of life in early 
stage prostate cancer, and in consultation with collaborating clinicians and consumers, 
and health services researchers who have experience with the estimation and 
interpretation of patient preference.  The DCE included nine attributes (Table 1). Seven 
of these represented common side-effects: two aspects of sexual dysfunction (impotence 
and libido), two aspects of urinary dysfunction (leakage and blockage), bowel symptoms 
(problems with bowel movements and associated pain), fatigue and hormonal effects (hot 
flushes and moodiness). There were two survival attributes: duration (mean life 
expectancy) and uncertainty (range of life expectancy).  
 
Each attribute was assigned three levels.  For the side-effects, the three levels generally 
reflected degree of severity, from no problems through mild to severe. The two attributes 
for life expectancy were combined on the questionnaire to provide a range (either low, 
medium or high) around an average life expectancy given in years - this was presented 




Two questionnaire designs were tested: two alternatives in each of 18 scenarios (“pairs”) 
versus three alternatives in each of 9 scenarios (“triples”).  In the first phase of the pilot 
involved six volunteers from the Cancer Council NSW, all of whom had been treated for 
prostate cancer. This phase recorded respondents’ preference for pairs or triples and time 
taken to complete each design. It also tested questionnaire wording and participants’ 
comprehension of the task.  In general, the material was understood, both designs were 
manageable (completion time ranged from 15-45 minutes) but the pair design was 
preferred. Suggestions regarding rewording were incorporated.  As the questionnaire was 
to be sent to participants by post and then followed up with a telephone interview using 
Computer Assisted Telephone Interview (CATI) software, the script and CATI system 
was pilot tested in the second phase.  Eligibility criteria and recruitment methods for this 
pilot were as for the main study, and 25 participants were recruited. The whole survey 
and data collection process worked well, feedback regarding the binding of the paper 




The statistical analysis of choice data relies on the random utility model (McFadden 
1981) where each respondents faces a choice amongst J alternatives repeated under S 
scenarios or choice situations. The utility that individual i derives from alternative j in 
scenario s is composed of systematic and random components denoted by 
 
(1)  isj isj isj V U ε + =   
 
 
isj isj isj X U ε β + ′ = ) 2 ( 
 
where Xisj  is a K x 1 vector of explanatory variables and β is a conformable vector of 
coefficients. 
 
In choosing between 2 alternatives in each scenario, it is assumed that person i chooses 
the alternative that gives him the maximum utility.  Then, the probability of choosing 
alternative 1 in scenario s is: 
 
(3)         Pis1 = P (U is1 > U is2) 
                    = P [(V is1+ 1 is ε ) > (Vis2+ 2 is ε )] 
                    = P [( 2 is ε - 1 is ε ) < (Vis1 - Vis2)] 
Assuming that the random components ( isj ε ) are identically and independently 
distributed (IID) as extreme value, the probability of the choice can be estimated by the 
binary logit model: 
 
















The logit specification is widely used in health economics research to model discrete 
choice data. Simplicity of estimation and interpretation are among the main advantages of 
this model.  However, there are some restrictive assumptions with this model that may be 
unrealistic in many situations.  
 
In general, variability (heterogeneity) among the people is expected.  Heterogeneity in 
preferences is a result of the inherent differences among individuals that can be attributed 
to their differences in tastes and decision making processes. Therefore, people with same 
observed characteristics may value and weight attributes of a product differently when 
making a decision. The binary logit specification can be generalized to account for this 
heterogeneity by allowing components of coefficients (β)  to randomly vary over 
individuals but not over the repeated choices made by an individual by setting: 
 
i k ki μ β β    + = ) 3 (     k = 1,…,K 
 
where k β  is the mean parameter vector for the population and  i μ  is the individual 
specific deviation from the mean. The i μ are assumed to follow standard normal 
distributions, independent of each other and of the εisj. This specification introduces error 
correlation across choice situations, accounting for the dependence structure in 
unobserved utility among the repeated choices of an individual which comes from panel 
structure of the data. This would be expected, since the same unobserved factors affect a 
specific respondent, to a certain degree, over the repeated choices made by him. This  
 
correlation is not perfect because of the presence of the independent extreme value terms 
εisj.  
 
Advances in computer power and simulation based methods have made the resultant 
random parameter or mixed logit (MXL) model computationally feasible to estimate and 
popular in empirical work (Revelt, Train 1998; Train 1998; Geweke, Keane 2001; Hall, 
Fiebig et al. 2006; Lancsar, Hall et al. forthcoming). Estimation by maximum simulated 
likelihood (MSL) was undertaken using a program downloaded from Kenneth Train's 
website (Train 2004). All estimation results reported below were generated using 1000 
Halton draws to simulate the likelihood functions to be maximized (Revelt, Train 1998; 
Brownstone, Train 1999; McFadden, Train 2000; Train 2003).  
 
McFadden and Train (2000) provide strong theoretical support for MXL when they prove 
that any well-behaved random utility model can be approximated to any specified degree 
of accuracy by a MXL model. Unfortunately this existence result does not lessen the 
practical problem of deciding what particular specification should be chosen. Further, it is 
important to recognize that the richer stochastic structure that results from the random 
parameter framework of MXL is a by-product of the model specification and simple 
changes in the specification of the systematic component of (1) may have major 
implications for the resultant stochastic structure.  
 
Welfare measurement and QALYs 
 
In welfare economics the compensating variation (CV) gives an exact monetary measure 
of change in welfare. It is most commonly used to determine the welfare impacts of price 
changes.  
 
Say the price of a good j falls from , income remains at the same level, Y, and 
utility falls rises from , where V is the systematic component of the utility 
function. CV is the reduction in income at the new price that would return an individual 
to the initial utility level.   
1 0   to p p
1 0   to V V
 
The welfare impact of the price rise is given by the CV: 
    ( ) ( )
0 0 1 , , V Y p V CV Y p V = = +  
If the price falls the individual is better off and CV is negative. If the price rises the 
individual is made worse off and the compensation is positive.  
 
The CV can also be expressed as the change in the expenditure necessary to achieve the 
original utility level  
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In health settings there are two major modifications to CV. The first is that choices are 
often mutually exclusive and discrete, for example treatment A or treatment B, so the 
probability of choosing different options is used rather than the quantity of a good. The 
second modification is that the focus is more often on quality changes, for example, 
changes in side effects associated with treatments than with price changes.  In this case 
the CV is given by: 
 
( ) ( ) ∫∫
∞∞
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If a logit specification is used to model the choice between J discrete and mutually 
exclusive alternatives, and if there is a quality change in alternative k, the CV can be 
written as  
 

















Or, more simply, for two mutually exclusive choices       
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where μ  denotes the marginal utility of income. The use of μ  converts utility changes 
into monetary units.  
 
It is possible to use other indexes for welfare change. For example, in health settings, 
survival time may be used to indicate the value of changes in quality of treatments such 
as different frequency and severity of side effects.  
 
Assume the utility function for the individual is defined over (chronic) health states and 
survival duration (see for example, Pliskin et al (1980). : 
 
() T h V V , =  
 
The welfare impact of a change in health state, from  to  , with no change in 
survival time, can be given by the change in survival time that would return the 
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If the change in health state is an improvement in quality of life, the individual is better 
off and CV is negative. For a decrement in quality of life the individual is made worse off 
and the compensation is positive.  
 
Thus, if an individual with an initial health state with no symptoms or side-effects (and a 
given life expectancy) experiences a decrease in quality of life (represented as a 
combination of symptoms and side-effects) as a result of disease and/or treatment, it is  
 
possible to determine the amount of additional survival time (increase in life expectancy) 
that would represent the same utility level as the initial health state. Survival time is the 
metric for measuring the welfare impacts of the change in health state, and in this case, 
μ  denotes the marginal utility of survival time.  
 
Thus, the CV can be used to provide a measure analogous to QALYs, given that a QALY 
is, by definition, a year of life in full health. If the QALY restrictions hold (Pliskin, 
Shepard et al. 1980; Bleichrodt, Wakker et al. 1997; Miyamoto, Wakker et al. 1998), this 
approach can be used to determine the QALY weight associated with any combination of 
symptoms and side-effects (defined as the ratio of survival duration without symptoms 
and side-effects that is equivalent in utility terms to the survival duration with the 




1,715 men aged less than 70 were diagnosed with prostate cancer between September 
2000 and December 2001 and identified by the NSW Cancer Registry as potentially 
eligible for PCOS. Consent was obtained for 1,067 (62%) of these men to participate in 
PCOS. A random sample of 510 of these men was invited to participate in the DCE 
substudy. 440 (86%) consented and 421 (83%) completed the DCE survey.  
Estimated model 
 
The estimated model is reported in Table 2. The intercept is the only random coefficient; 
this is a common way of capturing heterogeneity in panel data. This model allows for 
non-IID disturbances, but not for preference heterogeneity for attributes. This 
specification is also called the random effects model. In the next stage, we plan to 
estimate models with more parameters to be random to allow for preference 
heterogeneity for attributes. Some preliminary estimates from models with more random 
parameters have shown significant improvement in fit over the model with only intercept 
as random. 
 
For the estimated models, the log likelihood function values for the binary logit model 
(all the parameters fixed) and the reported mixed model are -3941.79 and -3937.57, 
respectively. This shows that the addition of just one extra variance parameter to allow 
for random individual effects yields an improvement in fit over the logit model. While 
these models are nested, the hypothesis tests are non-standard because the parameter 
space is restricted under the alternative. In such situations the LR test statistic does not 
have the usual chi-square asymptotic distribution (Andrews 1998). In this case, the 
appropriate critical value will be smaller than the usual chi-square value. Therefore, the 
LR test statistic of 8.44 for the comparison of the logit and MXL models will lead to 
rejecting the logit in favor of the MXL model at every reasonable significance level.  
  
 
Estimated coefficients for all attributes are statistically significant and generally have a 
sensible sign and magnitude. This implies that all the attributes were relevant to 
participants in choosing the treatment options for prostate cancer.  
 
The coefficients for seven side effect attributes were estimated as dummy coded with the 
no side effect level in each attribute as the omitted level. For instance, in the case of the 
attribute fatigue (level of physical energy): “No change in your energy level” was the 
omitted level; “Some tiredness and loss of energy” was fatigue 1 (mild); “Severe 
tiredness and loss of energy” was fatigue 2 (severe). Similar patterns were used for the 
other side effect attributes. Therefore, the expectation was that the estimated coefficients 
would be negative and the coefficient for the severe level to be bigger in magnitude than 
that of mild level. The results confirm this for five attributes: leakage, blockage, bowel 
symptoms, fatigue and hormonal effects. For example, the estimates for leakage 1 and 
leakage 2 are -0.0719 and -0.7991, respectively. The implication is that when compared 
to a treatment with no leakage problem, the respondents are less likely to choose a 
treatment with mild leakage problem and the likelihood of choosing is even lower for the 
treatment with severe problem.  
 
The coefficient estimates for the attributes related to sexual dysfunction, impotence and 
libido, do not have the same pattern as the other side effects. The severe levels for 
impotence and libido have the expected negative sign. However the mild level 
coefficients are positive suggesting that respondents would actually prefer mild sexual 
dysfunctions (eg, less sexual desire) compared to no problem. This may not be 
unexpected in this situation given the advanced age (average age is approximately 65) of 
the participants.    
 
The magnitude or size of the coefficient estimates also give an indication of the relative 
tolerability of the side effect attributes. Referring to the estimates in table 2, leakage 2 has 
the largest estimate in size implying that severe problems with leaking urine is the side 
effect that affects the choice of treatment the most (least preferable side effect). Severe 
problems with bowel movements and associated pain also have a big impact, nearly as 
big as severe leakage problem. In terms of the least tolerable (preferable) side effects, 
severe level of blockage was next, then severe level of fatigue and hormonal effects. 
Severe level of impotence and libido were more tolerable than mild levels of hormonal 
effects and bowel symptoms.      
 
One of the survival attributes is duration (average life expectancy), which was coded as 
continuous. As expected, the estimate for the attribute is positive, suggesting that 
respondents prefer more survival time and more likely to choose a treatment as the 
average life expectancy increases. Some caution is required in the interpretation of the 
remaining attribute, uncertainty (life expectancy range). The current specification of this 
attribute involves dummy coding with the low range as the omitted level. It seems from 
the positive estimates that the medium and high uncertainties are preferable compared to 
the low level. But it may be more appropriate to look into the effect of this attribute 
within the context of it’s complex interaction with the duration attribute. The issue has 
not been addressed in the current setting and needs further investigation.     
 
Welfare measurement and QALYS  
 
 
Table 3 presents the compensating variations, measured in units of survival time for each 
of the side-effects of treatment. The CVs indicate the number of additional years of 
survival necessary to compensate for the side effect. CVs are presented for initial life 
expectancies of 4, 8 and 12 years. For example, for a man expecting 4 years of survival 
without symptoms, 2.4 additional years of survival are required to compensate for the 
utility impact of a treatment which results in the side-effect of severe problems with 
leaking urine (leakage 2). At 8 and 12 years of survival the CVs for this side-effect 
increase to 3.1 and 3.6 years respectively. Consistent across life-expectancies, the three 
side-effects requiring the greatest compensation are leakage 2, bowel symptoms 2, and 
blockage 2. Fatigue 2 and hormonal effects 2 impose smaller losses of utility, but are next 
in rank terms. Interestingly, impotence 2 and libido 2 require less compensation than 
hormonal effects 1 and bowel symptoms 1. For the less severe levels of side-effects, the 
rank ordering differs, with greater compensation required for hormonal effects 1, bowel 
symptoms 1 and fatigue 1 than for leakage 1. The negative compensation for impotence 1 
and libido 1 may be explained by the initial health states of the respondents, because 
respondents may have already experienced or expected to experience symptoms 
equivalent or more severe to those represented by the milder levels of these side-effects 
in the experiment. 
 
Table 4 presents the number of years with the side-effect which is equivalent to 4, 8 and 
12 years respectively, that is, the implied time trade-off. Under the assumption that the 
QALY model holds, these values can be used to calculate the implied QALY weights for 
each health state. For example, the implied QALY weight for a health state in which an 
individual experiences severe problems with urine blockage is 0.68 at 4 years of life 
expectancy. From Table 4 it can be seen that the QALY weights of the health states 
depend on the survival duration, which is not consistent with the way that QALY weights 
are used in economic evaluation. It also suggests that it may be important in experiments 
designed to elicit QALY weights, to allow for interactions between health state and 
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Appendix - Example Scenarios  
Option A 
With this treatment option you will 
experience the following: 
Option B 
With this treatment option you will 
experience the following: 
 
Never able to achieve an erection when 
you want one 
 
No problems achieving an erection when 
you want one 
 
Less sexual desire 
 
Less sexual desire 
 
Severe problems with leaking urine  
(no urinary control whatsoever)
 
Occasional problems with leaking urine  
Some problems with urine blockage 
 (have a weak urine stream but get some 
relief or comfort afterwards) 
Some problems with urine blockage 
(have a weak urine stream but get some 
relief or comfort afterwards) 
 
No bowel problems 
 
Occasional loose bowel movements with 
discomfort/pain 
 
Severe tiredness and loss of energy 
 
Some tiredness and loss of energy 
 
Severe hot flushes and moodiness 
 
No hot flushes or moodiness 
Most people who have this option live 
between 3 and 21 years, but on average 
 for 
 






Most people who have this option live 
between 3 and 5 years, but on average 
 for 
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Option A………………..  OR    Option B………………..   
 
0  No 




0  No change in




0  No problems with leaking urine 
1  Occ ine  
Problems with urinating  
2  Severe problems with leaking urine (no urinary control whatsoever) 
0  No 
1  Som eak urine stream but 
get som
Pr
2  S eed to 
urinate but passing very little with no relief afterwards) 
ptoms 









Level of physical energy 
2  Severe tiredness and loss of energy 
7. H
0  No 
1  Mil
2  Sev
8. Life expectancy 
0 12  years   
1 8  years
2 4  ye
9. Life expectancy range 
0  Most people wh etween “X & Y” years, but 
on a
 
X a ibute 8 = 
2 (3  (9yrs – 15yrs)  
1  Mos  between ”X & Y” years, but 
on a
 
X and Y range (in brackets): if attribute 8 = 
2 (2 , 1 (4yrs – 12yrs), 0 (6yrs – 18 yrs)   
Life expectancy range 
 
Hi
2  Most people who have this option live between “X & Y” years, 
but  e for “Attribute 8” 
 
X and Y r ets): if attribute 8 = 





Table 1:  Attributes and Levels 
 
1. Impotence 
problems achieving an erection when you want one 
an erection when you want one  
er able to achieve an erection when you want one 
ality and frequency of erec
 sexual desire  Loss of se
plete loss of sexual desire 
asional problems with leaking ur
4. Blockage 
oblems with urinating   problems with urine blockage  
e problems with urine blockage (have a w
e relief or comfort afterwards) 
evere problems with urine blockage (continually feeling the n
5. Bowel sym
Pr bowel problems 
ional loose bowel movements with discomfort/pain  
y frequent loose bowel movements with discomfort/pain and 
eakage 
oblems with bowel movem
sociated pain  
o change in your energy level 
ome tiredness and loss of energy 
ormonal effects 
Hormones  hot flushes or moodiness 
d hot flushes and moodiness 
ere hot flushes and moodiness 
   
ars   
 
o have this option live b
verage for “Attribute 8” 
nd Y range (in brackets): if attr
yrs – 5yrs), 1 (6yrs – 10yrs), 0
t people who have this option live






ange (in brack 
 
Table 2: The model estimates 
 
Log-Likelihood Function value:  -3937.5
 
   rrors  p-value 
Intercept mean  -0.1387   0.0304   0.0000 
 st.dev  0.0000 
Impotence 1  dummy  0.0007 
Impotence 2  dummy  0.0091 
Libido 1  dummy  0.1183   0.0432   0.0062 
ibido 2  dummy  -0.0970   0.0411   0.0182 
Leakage 1  dummy  -0.0719   0.0385   0.0619 
eakage 2  dummy  -0.7991   0.0493   0.0000 
Blockage 1  dummy  -0.1332   0.0391   0.0007 
lockage 2  dummy  -0.6146   0.0446   0.0000 
ptoms 1  dummy  -0.1908   0.0366   0.0000 
owel symptoms 2  dummy  -0.7299   0.0514   0.0000 
-0.0945   0.0322   0.0034 
-0.3699   0.0363   0.0000 
5   0.0362   0.0000 
.3626   0.0482   0.0000 
ife expectancy   us   0.0098  
tancy range 1  y 
tancy range 2   
ompensating ons, measu n ts of s l  me h of the 
tmen
p ctancy
  4 yea y rs  s
otence -0.507 -0.616 -0.686 
6610217 
Estimates  St.e
0.2693   0.0605  
0.1414   0.0418  






Fatigue 1  dummy 
atigue 2  dummy  F
Hormonal effects 1  dummy  -0.241




















Table 3: C  variati red in u i urviva ti  for eac
side-effects of trea t. 
 
 
 Life  ex e  
rs  8  ea 12 year  
Imp   1 
Impotence 0.45 7      2  7 0.56 0.640
Libido  1  -0.422 -0.514 -0.573 
Libido  2  0.333 0.412    0.464
Leakage  1 0.248 0.307      0.345
Leakage  2  2.378 3.102 3.638 
Blockage  1  0.455 0.564 0.637 
Blockage  2  1.905 2.450 2.841 
Bowel symptoms 1  0.645  0.802  0.909 
Bowel symptoms 2  2.206  2.863  3.343 
Fatigue  1  0.325 0.402 0.453 
Fatigue  2  1.207 1.522 1.741 
Hormonal effects 1  0.808  1.010  1.146 




Table 4: The number of years with the side equivalent to 4, 8 and 12 
years respectively; the implied time  f a Y  
  Implied TTO values  Implied QALY weights 
  years  8 years ear rs  rs  12 years 
Impotence  1  3 7.384 .314 45 1.083 1.061 
-effect which is 
trade-of nd QAL  weights 
 
4    12 y s  4 yea 8 yea
3.49   11   1.1
Impotence  2  457 8.567 .640 97 0.934 0.949  4.   12   0.8
Libido  1  578 7.486 .427 18 1.069 1.050  3.   11   1.1
Libido  2  33 8.412 .464 23 0.951 0.963  4.3   12   0.9
Leakage  1  7 .345 42 0.963 0.972  4.248 8.30   12   0.9
Leakage 2  02 .638  27  21  0.767  6.378  11.1   15 0.6 0.7
Blockage  1  8.564 .637 98 0.934 0.950  4.455    12   0.8
Blockage 2  .905  10.450 .841  77  66  0.809  5   14 0.6 0.7
Bowel symptom 8.802 .909  61  09  0.930  s 1  4.645    12 0.8 0.9
Bowel symptom 63 .343  45  36  0.782  s 2  6.206  10.8   15 0.6 0.7
Fatigue  1  8.402 .453 25 0.952 0.964  4.325    12   0.9
Fatigue  2  5.207 9.522  13.741  0.768 0.840 0.873 
Hormonal effects 1  4.808  9.010  13.146  0.832  0.888  0.913 
Hormonal effects 2  5.185  9.494  13.707  0.772  0.843  0.875 
 
 
 